Oncology · NeuroblastomaTrial Updateclinicalmid-term

Phase I/II Trial of Iberdomide in Relapsed Neuroblastoma Shows Potential Efficacy

Importance8/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/9/2026, 12:31:31 PM

Assessment confidence: 75% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The ongoing phase I/II trial of iberdomide in relapsed neuroblastoma presents a significant opportunity for innovation in treatment protocols. A successful outcome could redefine standard care and enhance competitive positioning in the oncology market for neuroblastoma therapies. Regulatory context from FDA (Coronavirus (COVID-19) Update: FDA Issues Emergency Use Authorization for Potential COVID-19 Treatment) supports the near-term read. Assessment grounded in 20 ranked evidence items (13 high-relevance).

Strategic Assessment

If successful, this combination therapy may enhance treatment protocols and provide a competitive edge in the neuroblastoma market. The strongest clinical anchor is Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse (ClinicalTrials.gov), entity match (iberdomide); patient population match (refractory). In Oncology · Neuroblastoma, 2 regulatory and 4 competitive items passed relevance filtering for Iberdomide.

Competitive Pressure

The most relevant competitive pressure comes from Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial (Humanexa Signals) — sponsor/company relevance (roche). Secondary pressure from Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial. This trial could position iberdomide as a novel treatment option in a challenging patient population, potentially impacting existing therapies for neuroblastoma.

Regulatory Outlook

Regulatory risk is concentrated around Coronavirus (COVID-19) Update: FDA Issues Emergency Use Authorization for Potential COVID-19 Treatment (FDA). Moderate corpus alignment. The trial results will be critical for potential regulatory approvals, influencing labeling and compliance for iberdomide as a treatment option in this challenging patient population.

Key Risks

Elevated medium regulatory exposure for Iberdomide could delay market entry or constrain labeling if agency review intensifies.
Signal severity is high — leadership review is warranted.

Key Opportunities

If iberdomide proves effective, it could capture substantial market share, impacting revenue streams for existing neuroblastoma treatments and positioning the sponsoring entities favorably against competitors.
Upside for Iberdomide may improve if Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma (ClinicalTrials.gov) delivers favorable follow-through.
Upside for Iberdomide may improve if Umbilical cord blood natural killer cells improve anti-GD2 antibody efficacy in neuroblastoma: from mouse to human. (PubMed) delivers favorable follow-through.
Upside for Iberdomide may improve if Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL) (ClinicalTrials.gov) delivers favorable follow-through.
Upside for Iberdomide may improve if Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With CDK4/6 Inhibitor and an Aromata (ClinicalTrials.gov) delivers favorable follow-through.

What Would Change This Assessment

This becomes more urgent if Monitor trial results for safety and efficacy outcomes, as well as any regulatory developments related to iberdomide.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

Coronavirus (COVID-19) Update: FDA Issues Emergency Use Authorization for Potential COVID-19 Treatment
FDAhigh relevance
Moderate corpus alignment
FDA document
View source
Coronavirus (COVID-19) Update: FDA Warns of Newly Discovered Potential Drug Interaction That May Reduce Effectiveness of COVID-19 Treatment Authorized for Emergency Use
FDAhigh relevance
Moderate corpus alignment
FDA document
View source

Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse
ClinicalTrials.govhigh relevance
Entity match (iberdomide); Patient population match (refractory)
FDA document
View source
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
ClinicalTrials.govhigh relevance
Entity match (national cancer institute); Patient population match (refractory)
FDA document
View source
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
ClinicalTrials.govhigh relevance
Entity match (national cancer institute)
FDA document
View source
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
ClinicalTrials.govhigh relevance
Entity match (national cancer institute)
FDA document
View source
Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)
ClinicalTrials.govhigh relevance
Patient population match (refractory)
FDA document
View source
Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines
ClinicalTrials.govhigh relevance
Entity match (national cancer institute)
FDA document
View source
Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With CDK4/6 Inhibitor and an Aromata
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Novartis)
FDA document
View source
Phase I Trial of Pacritinib in Combination With Venetoclax and Azacitidine for the Treatment of Accelerated and Blast Phase Myeloproliferative Neoplasms
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
HPV Vaccination Shows High Efficacy Against Cancer and Precancer Outcomes
Humanexa Signalsmedium relevance
Moderate corpus alignment
Phase 1 Trial of LMP744 in Recurrent Glioblastoma Shows Potential for New Treatment
Humanexa Signalsmedium relevance
Moderate corpus alignment

Umbilical cord blood natural killer cells improve anti-GD2 antibody efficacy in neuroblastoma: from mouse to human.
PubMedhigh relevance
Entity match (neuroblastoma)
FDA document
View source
Deep learning based on CD3 histological slides for prediction of colon cancer outcome: analysis of three international stage III colon cancer cohorts.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Efficacy of vunakizumab in patients with moderate-to-severe plaque psoriasis across diverse disease features: a post hoc analysis of a phase-III trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
The role of capacitive hyperthermia as an adjunct treatment in oncology: a systematic review of randomized phase III trials.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Gut microbial metabolism of Flutamide attenuates its therapeutic efficacy against prostate cancer.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Trial watch: antibody-drug conjugates in cancer therapy.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Iberdomide
Neuroblastoma
National Cancer Institute

Commercial impact

high

If iberdomide proves effective, it could capture substantial market share, impacting revenue streams for existing neuroblastoma treatments and positioning the sponsoring entities favorably against competitors.

Regulatory impact

medium

The trial results will be critical for potential regulatory approvals, influencing labeling and compliance for iberdomide as a treatment option in this challenging patient population.

What to watch

Monitor trial results for safety and efficacy outcomes, as well as any regulatory developments related to iberdomide.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.